Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
If this keeps happening, a symptom diary can help
Eli Lilly's Phase 3 obesity programme for retatrutide (master protocol J1I-MC-GZBJ) remains in active follow-up with no NDA (New Drug Application) or MAA (Marketing Authorisation Application) filing recorded in 20242026 pipeline disclosures [1][2]
Clinical trials show that patients typically see: Wegovy: An average of about 15% total body weight loss over 68 weeks
Wegovy is approved for weight management at higher doses
Underlying mechanisms involve improved glycemic control, but also increased nitric oxide bioavailability, reduced oxidative stress and, for certain molecules, a direct inhibition of platelet activation and aggregation
US$ 22.51
US$ 22.02
US$ 27.90
US$ 26.95
